Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
In preclinical models ARQ 531 demonstrates potent anti-tumor activity in DLBCL BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models was presented at EHA Congress
View HTML
Toggle Summary ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
Trial will enroll patients with Overgrowth Diseases driven by the PI3K/AKT1 pathway BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a company sponsored phase 1/2 trial with its AKT inhibitor, ARQ 092, in patients with
View HTML
Toggle Summary ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
83% disease control rate observed in intrahepatic cholangiocarcinoma FGFR2 positive patients BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that data from a phase 1/2 trial with fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, presented at ASCO
View HTML
Toggle Summary ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
Data strengthens preclinical profile for ARQ 531 BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models will be presented on June 23, 2017 at EHA Congress in
View HTML
Toggle Summary ArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Data will be presented from the Phase 1/2 trial of ARQ 087 in intrahepatic cholangiocarcinoma BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that data from the phase 1/2 trial in intrahepatic cholangiocarcinoma (iCCA) with fibroblast growth factor receptor (FGFR)
View HTML
Toggle Summary Arqule Reports First Quarter 2017 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2017. For the quarter ended March 31, 2017 , the Company reported a net loss of $7,576,000 or $0.11 per share, compared
View HTML
Toggle Summary ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 9,630,968. The patent claims composition of matter of ARQ 531. ArQule will be entitled to patent protection through December 2035 in the U.S.
View HTML
Toggle Summary ArQule To Report First Quarter 2017 Financial Results On May 3, 2017
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter 2017 before the market opens on Wednesday, May 3, 2017 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531
Plan to initiate a phase 1 trial by Q3 of 2017 BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application to conduct a phase 1 clinical trial
View HTML
Toggle Summary ArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Brian Schwartz , M.D., Chief Medical Officer and Head of Research and Development, will present at the 16 th Annual Needham Healthcare Conference on April 4 th ,
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.